Patent Application
20190147976
The field of the invention is computational analysis of various omics data to allow for treatment stratification for immune therapy, and especially pathway-based analysis to identify likely responders to checkpoint inhibitor treatment.
The background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
All publications herein are incorporated by reference to the same extent as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
Immune therapy with genetically modified viruses has become increasingly effective and attractive route for treatment of various cancers. However, several challenges remain to be resolved. For example, the choice of suitable antigens to be expressed is non-trivial (see e.g., Nat Biotechnol. 2012; 30(7):658-70; and Nat Biotechnol. 2017; 35(2): 79). Moreover, even frequently or highly expressed epitopes will not guarantee a tumor-protective immune reaction in all patients. In addition, even where several neoepitopes are known and used as an immunotherapeutic composition, inhibitory factors in the tumor microenvironment may nevertheless prevent a therapeutically effective response. For example, a sufficient immune response may be blunted or even prevented by Tregs (i.e., regulatory T cells) and/or MDSCs (myeloid derived suppressor cells). In addition, lack of stimulatory factors and tumor based interference with immune checkpoints, and especially PD-1 and CTLA-4, may still further prevent a therapeutic response to immune therapy.
Therapeutic compositions are known to block or silence immune checkpoints (e.g., Pembrolizumab or Nivolumab for the PD-1 system, or Ipilimumab for the CTLA-4 system). However, administration is not consistently effective to promote a durable and therapeutically useful response. Likewise, cyclophosphamide may be used to suppress Tregs, however tends to mobilize MDSCs. Thus, a clear path to intervention in patients with low immune response to immune therapy is not apparent. More recently, a predictive model was proposed that used levels of tumor MHC class I expression as a positively correlated marker with overall tumor immunogenicity (see J Immunother 2013, Vol. 36, No 9, p 477-489). The authors also noted a pattern where certain immune activating genes were up-regulated in strongly immunogenic tumors of some of the models, but advised that additional biomarkers should be found to help predict immunotherapy response. In another approach (Cancer Immunol Res; 4(5) May 2016, OF1-7), post-treatment in depth sequence and distribution analysis of tumor reactive T cell receptors was used as a proxy indicator for reactive T-cell tumor infiltration. Unfortunately, such analysis fails to provide predictive insight with respect to likely treatment success for immune therapy.
In still further known approaches, change in expression level of selected genes was used as a signature predictive of increased likelihood of being responsive to immunotherapy as described in WO 2016/109546. Similarly, US 2016/0312295 and US 2016/0312297 teach gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. While such signatures tend to be at least somewhat informative, they are generally ‘static’ and typically fail to reflect pathway activity that could be indicative of sensitivity and/or susceptibility to treatment with one or more checkpoint inhibitors.
Thus, even though various systems and methods of immune therapy and checkpoint inhibition are known in the art, all or almost all of them suffer from several drawbacks. Therefore, there is still a need to provide improved compositions and methods to identify patients that are responsive to immune therapy and treatment with checkpoint inhibitors.
The inventive subject matter is directed to computational analysis of omics data to predict likely treatment success to immune therapy using checkpoint inhibitors. In one particularly preferred aspect, computational pathway analysis is performed on omics data obtained from a tumor sample (e.g., breast cancer tumor sample containing tumor infiltrating lymphocytes), wherein the pathway analysis uses a cluster of features and pathways that are associated with specific subsets of immune related genes. In still further preferred aspects, the features and pathways are associated with an up-regulated FOXM1 signaling pathway, with the presence and/or inhibition of tumor infiltrating lymphocytes, with a low (as compared to healthy tissue) Th1/Th2 ratio, and with a basal-like character.
In one aspect of the inventive subject matter, the inventors contemplate a method of predicting a likely therapeutic outcome for immune therapy of a cancer with a checkpoint inhibitor (e.g., CTLA-4 or a PD-1 inhibitor). Preferred methods comprise a step of obtaining omics data from a tumor of the patient, wherein the omics data comprise at least one of whole genome sequencing data and RNA sequencing data, and a further step of using pathway analysis to identify from the omics data a plurality of highly expressed genes in a plurality of immune related pathways having a plurality of respective pathway elements. In another step, the highly expressed genes are associated with a likely response of the cancer to treatment with the checkpoint inhibitor when the highly expressed genes are indicative of a Th2/humoral response and a low Th1/Th2 ratio, and in a still further step, a patient record is updated or generated record with an indication of the likely response of the cancer to treatment with the checkpoint inhibitor when the highly expressed genes are indicative of a Th2/humoral response and a low Th1/Th2 ratio.
Preferred immune related pathways include an immune cell function pathway, a pro-inflammatory signaling pathway, and an immune suppression pathway, and/or the pathway element controls activity of Th1 differentiation, Th2 differentiation, B cell differentiation, macrophage differentiation, T cell activation, and/or an immunoproteasome. For example, while some contemplated pathway elements will control activity of NFkB, and/or IFNalpha responsive gen, other pathway elements include cytokines, and especially IL12 beta, IFNgamma, IL4, IL5, and IL10. Further contemplated pathway elements include one or more chemokines, including CCL17, CCL11, and CCL26.
Therefore, and among other suitable pathway elements, especially contemplated elements are selected form the group consisting of IL12B, IFNG, PSMA3, THY1, CCL17, PRKCQ, NFATC3, NFATC2, CCL11, CCL26, IFNAR2, SQSTM1, IRAK4, NFKBIA, IL6ST, MAP3K1, IRF1, IRF9, PTGS2, IL4, IL5, IGHG3, IL4R, IL13RA2, PIGR, IL13RA1, STAT6, FCER2, IGHG1, IL10, STAT5A, PRKCE, CSF1R, ARG1, LTA, SELP, FKBP3, LCP2, and DOK2. Where the pathway element is a complex, especially contemplated complexes are selected form the group consisting of IFN-gamma/IRF1, STAT6 (dimer)/PARP14, IL4/IL4R/JAK1, IL4R/JAK1, STAT6 (dimer)/ETS1, PI3K/BCAP/CD19, IL4/IL4R/JAK1/IL2Rgamma/JAK3/DOK2, IL4/IL4R/JAK1/IL2Rgamma/JAK3/SHIP, IL4/IL4R/JAK1/IL13RA1/JAK2, IL4/IL4R/JAK1/IL2Rgamma/JAK3/SHC/SHIP, IL4/IL4R/JAK1/IL2Rgamma/JAK3/FES/IRS2, IL4/IL4R/JAK1/IL2Rgamma/JAK3, IL4/IL4R/JAK1/IL2Rgamma/JAK3/SHC/SHIP/GRB2, IL4/IL4R/JAK1/IL2Rgamma/JAK3/IRS1, IL4/IL4R/JAK1/IL2Rgamma/JAK3/FES, IL4/IL4R/JAK1/IL2Rgamma/JAK3/SHP1.
In further contemplated aspects, the omics data may further comprise siRNA data, DNA methylation status data, transcription level data, and/or proteomics data. Most preferably, the pathway analysis comprises PARADIGM analysis, and/or the omics data are normalized against the same patient (before or after treatment). Typically, the cancer is a breast cancer, and the highly expressed genes will further include FOXM1. However, contemplated highly expressed genes may further include non-immune genes encoding a protein involved in at least one of mitogenic signaling, stress signaling, apoptosis, calcium/calmodulin signaling, G-protein signaling, PI3K/AKT signaling, RTK signaling, Wnt signaling, and cAMP signaling, non-immune genes encoding a protein involved in at least one of cell cycle control, DNA damage response, and chromatin remodeling, and/or non-immune genes selected from the group consisting of MAPK1, MAPK14, NRP2, HIF1A, CALM1, CREB1, CSNK1A1, CSNK1G3, CCNH, FANCE, FANCA, TFIIH, ITGB3, RASA1, GNG2, PDGFRB, AKT1, and PIK3R1. In further contemplated methods, the likely therapeutic outcome is predicted prior to therapy with the checkpoint inhibitor, and/or the immune therapy may further comprise administration of at least one of a genetically modified virus and a genetically modified NK cell.
Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments, along with the accompanying drawing.
The inventors have discovered systems and methods of predicting a likely treatment outcome of cancer immune therapy by computational analysis of pathway signatures found in tumor tissue to identify the immune status of a tumor. In especially preferred aspects of the inventive subject matter, positive treatment outcome with checkpoint inhibitors is predicted in breast cancer where a tumor has attributes of an up-regulated FOXM1 signaling pathway, with presence and/or inhibition of tumor infiltrating lymphocytes, with a low (as compared to healthy tissue) Th1/Th2 ratio, and with a basal-like character.
In this context, it should be appreciated that contemplated systems and methods take advantage of differentially expressed genes (using mRNA quantity and copy number as the main contributors) in pathways versus the same genes in healthy tissue as predictor. Most typically, differentially expressed genes will be up-regulated relative to the same genes in healthy tissue, however, down-regulated genes are also contemplated (and often present in genes associated with Th1 phenotype). Moreover, it should also be recognized that pathway analysis (e.g., using PARADIGM) provides a significant advantage in such analysis identifies active pathways in subsets of patients that would otherwise be indistinguishable where genes are studied at a single level. Particularly preferred methods of pathway analysis make use of techniques from probabilistic graphical models to integrate functional genomics data onto a known pathway structure. Such analysis not only provides better discrimination of patients with respect to prognosis than any of the molecular levels studied separately, but also allows for identification of immune status of a tumor based on characteristics that are reflected in specific immune related pathway activities, and particularly with FOXM1 signaling pathway activity, activity of Th1 and Th2 related pathways, pathway activity associated with innate immunity, and pathways associated with sub-type of cancer (e.g., luminal, basal). Indeed, clustering of results from pathway analysis revealed distinct groups of differential pathway activity as is discussed in more detail below.
For example, and as discussed in more detail below, the inventors observed that all clusters that were associated with good outcome (increased survival time) were significantly enriched in genes associated with antitumor immunity at the expense of the Th2/humoral immune response, which is also consistent with a higher ratio of Th1/Th2 genes in these clusters. On the other hand, the cluster that was associated with poorer outcome (decreased survival time) was significantly enriched in Th2/humoral-related genes and had significantly lower Th1/Th2 ratios. Notably, the inventors discovered that the pathway activities in such cluster was also prognostic for treatment success with one or more checkpoint inhibitors.
Consequently, it is contemplated that prior to treatment (or after one round of cancer treatment but before a subsequent round of cancer treatment), a tumor biopsy is obtained from a patient and that omics analysis is performed on the so obtained sample. In general, it is contemplated that the omics analysis includes whole genome and/or exome sequencing, RNA sequencing and/or quantification, and/or proteomics analysis. Most typically, the omics analysis will also include obtaining information about copy number alterations, especially amplification of one or more genes. As will be readily appreciated, it is contemplated that genomic analysis can be performed by any number of analytic methods, however, especially preferred analytic methods include next generation WGS (whole genome sequencing) and exome sequencing of both a tumor and a matched normal (healthy tissue of same patient) sample. Alternatively, the matched normal sample may also be replaced in the analysis by a reference sample (typically representative of healthy tissue). Moreover, the matched normal or reference sample may be from the same tissue type as the tumor or from blood or other non-tumor tissue.
Computational analysis of the sequence data may be performed in numerous manners. In most preferred methods, however, analysis is performed in silico by location-guided synchronous alignment of tumor and normal samples as, for example, disclosed in US 2012/0059670 and US 2012/0066001 using BAM files and BAM servers. Of course, alternative file formats (e.g., SAM, GAR, FASTA, etc.) are also expressly contemplated herein. Regardless of the manner of analysis, contemplated DNA omics data will preferably include information about copy number, patient- and tumor specific mutations, and genomic rearrangements, including translocations, inversions, amplifications, fusion with other genes, extrachromosomal arrangement (e.g., double minute chromosome), etc.
Likewise, RNA sequencing and/or quantification can be performed in all manners known in the art and may use various forms of RNA. For example, preferred materials include mRNA and primary transcripts (hnRNA), and RNA sequence information may be obtained from reverse transcribed polyA+-RNA, which in turn obtained from a tumor sample and a matched normal (healthy) sample of the same patient. Likewise, it should be noted that while polyA+-RNA is typically preferred as a representation of the transcriptome, other forms of RNA (hn-RNA, non-polyadenylated RNA, siRNA, miRNA, etc.) are also deemed suitable for use herein. Preferred methods also include quantitative RNA (hnRNA or mRNA) analysis and/or quantitative proteomics analysis. Most typically, RNA quantification and sequencing is performed using qPCR and/or rtPCR based methods, although other methods (e.g., solid phase hybridization-based methods) are also deemed suitable. Therefore, and viewed from another perspective, transcriptomic analysis may be suitable (alone or in combination with genomic analysis) not only for quantification of transcripts, but also to identify and quantify genes that have tumor- and patient specific mutations.
Similarly, proteomics analysis can be performed in numerous manners, and all known manners or proteomics analysis are contemplated herein. However, particularly preferred proteomics methods include antibody-based methods and mass spectroscopic methods. Moreover, it should be noted that the proteomics analysis may not only provide qualitative or quantitative information about the protein per se, but may also include protein activity data where the protein has catalytic or other functional activity. One example of technique for conducting proteomic assays includes U.S. Pat. No. 7,473,532 to Darfler et al. titled “Liquid Tissue Preparation from Histopathologically Processed Biological Samples, Tissues, and Cells” filed on Mar. 10, 2004. Still other proteomics analyses include mass spectroscopic assays, and especially MS analyses based on selective reaction monitoring.
The so obtained omics data are then further processed to obtain pathway activity and other pathway relevant information using various systems and methods known in the art. However, particularly preferred systems and methods include those in which the pathway data are processed using probabilistic graphical models as described in WO 2011/139345 and WO 2013/062505, or other pathway models such as those described in WO 2017/033154, all incorporated by reference herein. Thus, it should be appreciated that pathway analysis for a patient may be performed from a single patient sample and matched control (once before treatment, or repeatedly, during and/or after treatment), which will significantly improve and refine analytic data as compared to single omics analysis that is compared against an external reference standard. In addition, the same analytic methods may further be refined with patient specific history data (e.g., prior omics data, current or past pharmaceutical treatment, etc.).
Once pathway activity from the omics data of the tumor sample has been calculated, differentially activated pathways and pathway elements (e.g., relative to ‘normal or patient-specific normal) in the output of the pathway analysis are then analyzed against a signature that is characteristic for an immune suppressed tumor. Most typically, such signature has the features and pathways that are associated with an up-regulated FOXM1 signaling pathway, with the presence and/or inhibition of tumor infiltrating lymphocytes, with a low (as compared to healthy tissue) Th1/Th2 ratio, and with a basal-like character.
In one exemplary aspect, and as is discussed in more detail below, the signature of an immune suppressed tumor is based on the most significant portion (e.g., top 500 features, top 200 features, top 100 features) of pathway features from patient groups clusters identified in a machine learning environment. For example, pathway analysis was performed for breast cancer patients in which one group (MicMa) had good outcome as evidenced by overall survival while another group (Chin/Naderi) had poor outcome as evidenced by overall survival. Here, pathway analysis allowed for definition of five different clusters in which the clusters were characterized as follows: PDGM1=high FOXM1, high Th1/Th2 ratio, basal/ERBB2; PDGM2=high FOXM1, low Th1/Th2 ratio, basal; PDGM3=high FOXM1, innate immune genes, macrophage dominated, luminal; PDGM4=high ERBB4, low angiopoietin signaling, luminal; and PDGM5=low FOXM1, low macrophage signature, luminal A.
Of course, it should be appreciated that numerous other groupings and clusters can be used to differentiate likely treatment outcomes. For example, suitable clusters may be based on specific tumor types, patient sub-populations, and may be larger or smaller. Moreover, it should be noted that contemplated systems and methods may also be based on or include specific neoepitopes and/or T cell receptors with specificity to one more tumor related epitopes (e.g., neoepitopes or cancer associated epitopes). In such case, expression of a specific neoepitope (especially a HLA-matched neoepitope) may be used as a proxy marker for immunogenicity. On the other hand, expression and/or quantity of a T cell receptor that binds a specific epitope may be used as a marker for immunogenicity. Similarly, it is noted that the distribution (e.g., between tumor and circulating blood) of T cell receptors specific to a neoepitope may be used as an indicator for immunogenicity. Likewise, expression of the patient's MHC-I may be ascertained and quantified to obtain a further measure of immunogenicity. In this context, it should be appreciated that this information can be readily obtained from the omics data and that omics analysis will advantageously eliminate the need for ex vivo immune staining protocols.
Regardless of the particular clustering or grouping employed, it is contemplated that the differential pathway activities of the patient are identified and compared against the signature that is indicative of an immune suppressed tumor (comprises features and pathway activities associated with an up-regulated FOXM1 signaling pathway, with the presence and/or inhibition of tumor infiltrating lymphocytes, with a low Th1/Th2 ratio, and with a basal-like character). Such comparison may include a comparison of one or more selected features that are representative of specific pathways (e.g., identification of expression level of selected genes encoding proteins that are part of a specific signaling pathway) or may include a comparison of a set of features, where a degree of similarity is identified (e.g., at least 50%, 60%, 70%, or 80% of overexpressed genes in tumor are also overexpressed in feature set of the signature. Upon determination that the patient data match or are consistent with the signature that is characteristic for immune suppression, treatment with a checkpoint may be advised (e.g., by generating or updating a patient record with an indication that checkpoint inhibition may be effective).
Identification of breast cancer related pathways was performed using data sets from patient populations with known history. MicMa patients with breast cancer (n=101) in this study were part of a cohort of patients treated for localized breast cancer from 1995 to 1998. Samples from the UPPSALA cohort, collected at the Fresh Tissue Biobank, Department of Pathology, Uppsala University Hospital, were selected from a population-based cohort of 854 women diagnosed between 1986 and 2004 with one of three types of primary breast cancer lesions: (a) pure DCIS, (b) pure invasive breast cancer 15 mm or less in diameter, or (c) mixed lesions (invasive carcinoma with an in situ component). The Mammographic Density and Genetics cohort, including 120 healthy women with no malignant disease but some visible density on mammograms, referred to here as healthy women, was included in this study. Two breast biopsies and three blood samples were collected from each woman. The Chin validation set consisted of 113 tumor samples with both expression (GEO accession no. GSE6757) and CGH data (MIAMEExpress accession E-Ucon-1). The UNC validation dataset consisted of 78 tumor samples with both expression (44 K; Agilent Technologies) and SNP-CGH (109 K; Illumina).
Data preprocessing and PARADIGM parameters were as follows: Copy number was segmented using circular binary segmentation (CBS) and then mapped to gene-level measurements by taking the median of all segments that span a RefSeq gene's coordinates in hg18. For mRNA expression, measurements were first probe-normalized by subtracting the median expression value for each probe. The manufacturer's genomic location for each probe was converted from hg17 to hg18 using University of California, Santa Cruz liftOver tool. Per-gene measurements were then obtained by taking the median value of all probes overlapping a RefSeq gene. Methylation probes were matched to genes using the manufacturer's description. PARADIGM was run as it previously described (Bioinformatics 26:i237ei245), by quantile-transforming each dataset separately, but data were discretized into bins of equal size rather than at the 5% and 95% quantiles. Pathway files were from the Pathway Interaction Database (Nucleic Acids Res 37: D674eD679) as previously parsed.
HOPACH unsupervised clustering: Clusters were derived using the HOPACH R implementation version 2.10 (J Stat Planning Inference 117:275e303) running on R version 2.12. The correlation distance metric was used with all data types, except for PARADIGM IPLs, which used cosangle because of the nonnormal distribution and prevalence of zero values. For any cluster of samples that contained fewer than five samples, each sample was mapped to the same cluster as the most similar sample in a larger cluster. PARADIGM clusters in the MicMa dataset were mapped to other data types by determining each cluster's mediod (using the median function) in the MicMa dataset and then assigning each sample in another dataset to whichever cluster mediod was closest by cosangle distance. The copy number was clustered on gene-level values rather than by probe. The values that went into the clustering are from the CBS segmentation of each sample. A single value was then generated for each gene by taking the median of all segments that overlap the gene. The samples were then clustered using these gene-level copy number estimates with an uncentered correlation metric in HOPACH. For display, the genes and samples were median-centered.
Notably, unsupervised clustering in the pathway analysis lead to a sub-typing into distinct clusters with differential survivals, and the inventors unexpectedly discovered that the genes that strongly associated with each cluster defining the subtypes were largely immune-based. Notably, genes associated with good outcome as evidenced by overall survival were found to coincide with Th1 cells and Th1 signaling, cytotoxic T cells, and natural killer cells as can be seen from
The most significantly differentially expressed pathways and genes that comprise the PARADIGM2 cluster are summarized in the tables below. More specifically, the tables below list exemplary immune related features within the top 500 features in the cluster that was associated with high FOXM1, low Th1/Th2 ratio, and basal character, for both good and poor outcome groups. Table 1 lists pathway entities (individual proteins or complexes) that are located in immune related pathways and that are differentially regulated relative to healthy tissue. These entities were from a subgroup of negative outcome patients.
Table 2 lists pathway entities (individual proteins or complexes) that are located in non-immune related pathways and that are differentially regulated relative to healthy tissue these entities are from a subgroup of positive outcome patients. These entities were from a subgroup of negative outcome patients.
Table 3 lists pathway entities (individual proteins or complexes) that are located in immune related pathways and that are differentially regulated relative to healthy tissue. These entities were from a subgroup of positive outcome patients.
Table 4 lists pathway entities (individual proteins or complexes) that are located in non-immune related pathways and that are differentially regulated relative to healthy tissue these entities are from a subgroup of positive outcome patients. These entities were from a subgroup of positive outcome patients.
While all of the above pathway entities, when differentially expressed relative to normal (overexpressed or underexpressed) may serve as indicators for an immune suppressed tumor, it is contemplated that only a fraction may be analyzed. For example, suitable tests may analyze at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90% of the genes/pathway entities listed in Tables 1-4. Alternatively, contemplated tests may also use specific genes of the genes/pathway entities listed in Tables 1-4, and especially one or more of pathway elements selected form the group consisting of IL12B, IFNG, PSMA3, THY1, CCL17, PRKCQ, NFATC3, NFATC2, CCL11, CCL26, IFNAR2, SQSTM1, IRAK4, NFKBIA, IL6ST, MAP3K1, IRF1, IRF9, PTGS2, IL4, IL5, IGHG3, IL4R, IL13RA2, PIGR, IL13RA1, STAT6, FCER2, IGHG1, IL10, STAT5A, PRKCE, CSF1R, ARG1, LTA, SELP, FKBP3, LCP2, and DOK2. For example, such list may include at least two, at least three, at least four, at least five, at least ten, at least 15, or at least 20 of IL12B, IFNG, PSMA3, THY1, CCL17, PRKCQ, NFATC3, NFATC2, CCL11, CCL26, IFNAR2, SQSTM1, IRAK4, NFKBIA, IL6ST, MAP3K1, IRF1, IRF9, PTGS2, IL4, IL5, IGHG3, IL4R, IL13RA2, PIGR, IL13RA1, STAT6, FCER2, IGHG1, IL10, STAT5A, PRKCE, CSF1R, ARG1, LTA, SELP, FKBP3, LCP2, and DOK2.
In addition, contemplated assays need not only be limited to single pathway elements, but may also include complexes of pathway elements, and especially one or more complexes selected from the group consisting of IFN-gamma/IRF1, STAT6 (dimer)/PARP14, IL4/IL4R/JAK1, IL4R/JAK1, STAT6 (dimer)/ETS1, PI3K/BCAP/CD19, IL4/IL4R/JAK1/IL2Rgamma/JAK3/DOK2, IL4/IL4R/JAK1/IL2Rgamma/JAK3/SHIP, IL4/IL4R/JAK1/IL13RA1/JAK2, IL4/IL4R/JAK1/IL2Rgamma/JAK3/SHC/SHIP, IL4/IL4R/JAK1/IL2Rgamma/JAK3/FES/IRS2, IL4/IL4R/JAK1/IL2Rgamma/JAK3, IL4/IL4R/JAK1/IL2Rgamma/JAK3/SHC/SHIP/GRB2, IL4/IL4R/JAK1/IL2Rgamma/JAK3/IRS1, IL4/IL4R/JAK1/IL2Rgamma/JAK3/FES, IL4/IL4R/JAK1/IL2Rgamma/JAK3/SHP1 (or any combination of at least two, at least three, at least four, at least five, or at least ten complexes).
In addition, the differentially expressed genes may include highly expressed genes, and especially FOXM1. Still further contemplated differentially expressed genes include non-immune genes that encode a protein involved in at least one of mitogenic signaling, stress signaling, apoptosis, calcium/calmodulin signaling, G-protein signaling, PI3K/AKT signaling, RTK signaling, Wnt signaling, and cAMP signaling, or non-immune genes encoding a protein that is involved in at least one of cell cycle control, DNA damage response, and chromatin remodeling as shown in Tables 2 and 4 above. For example, suitable contemplated non-immune genes include at least one, at least two, at least three, at least four, at least five, at least ten MAPK1, MAPK14, NRP2, HIF1A, CALM1, CREB1, CSNK1A1, CSNK1G3, CCNH, FANCE, FANCA, TFIIH, ITGB3, RASA1, GNG2, PDGFRB, AKT1, and PIK3R1.
It should be apparent to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. The inventive subject matter, therefore, is not to be restricted except in the scope of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms “comprises” and “comprising” should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced. Where the specification claims refers to at least one of something selected from the group consisting of A, B, C . . . and N, the text should be interpreted as requiring only one element from the group, not A plus N, or B plus N, etc.
This application claims priority to U.S. provisional application Ser. No. 62/332,047, filed May 5, 2016. U.S. application No. 62/332,047 is incorporated herein in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US17/31418 | 5/5/2017 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62332047 | May 2016 | US |
